Advertisement

Advertisement

AU:NOX Stock Latest News

Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market

Company AnnouncementsNoxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market

Noxopharm outlines precision therapy pipeline and clarifies trial links

PremiumCompany Announcements

Noxopharm outlines precision therapy pipeline and clarifies trial links

15d ago

Noxopharm’s SOF-SKN Trial Completion: Early Safety Milestone for a New Lupus Skin Therapy

PremiumCompany Announcements

Noxopharm’s SOF-SKN Trial Completion: Early Safety Milestone for a New Lupus Skin Therapy

16d ago

Noxopharm’s Sofra Oligos Show Promise in Reducing mRNA Vaccine Reactogenicity

PremiumCompany Announcements

Noxopharm’s Sofra Oligos Show Promise in Reducing mRNA Vaccine Reactogenicity

18d ago

Noxopharm Narrows Annual Loss but Net Tangible Assets Turn Negative

PremiumCompany Announcements

Noxopharm Narrows Annual Loss but Net Tangible Assets Turn Negative

22d ago

Noxopharm Preclinical Data Bolsters Sofra Immuno-Oncology Platform

PremiumCompany AnnouncementsNoxopharm Preclinical Data Bolsters Sofra Immuno-Oncology Platform

24d ago

Noxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy

Company Announcements

Noxopharm Data Validate TLR8-Targeted Oligonucleotide Cancer Strategy

2M ago

Noxopharm advances Sofra platform as SOF-SKN nears FDA milestone

Company Announcements

Noxopharm advances Sofra platform as SOF-SKN nears FDA milestone

2M ago

Noxopharm moves SOF-SKN toward U.S. FDA pathway to boost autoimmune portfolio

PremiumCompany Announcements

Noxopharm moves SOF-SKN toward U.S. FDA pathway to boost autoimmune portfolio

2M ago

Noxopharm Sofra Platform Backed in $1m Grant for Childbirth Injury Treatment

PremiumCompany Announcements

Noxopharm Sofra Platform Backed in $1m Grant for Childbirth Injury Treatment

3M ago

Noxopharm unveils human-like TLR8 model to accelerate cancer immunotherapy program

PremiumCompany Announcements

Noxopharm unveils human-like TLR8 model to accelerate cancer immunotherapy program

3M ago

Noxopharm Starts SOF-SKN Manufacturing Ahead of Cutaneous Lupus Trial

PremiumCompany Announcements

Noxopharm Starts SOF-SKN Manufacturing Ahead of Cutaneous Lupus Trial

3M ago

Noxopharm Director Restructures Holding Via Off-Market Share Transfer

PremiumCompany AnnouncementsNoxopharm Director Restructures Holding Via Off-Market Share Transfer

4M ago

Noxopharm Showcases Potent New TLR8-Based Immuno-Oncology Platform

Company Announcements

Noxopharm Showcases Potent New TLR8-Based Immuno-Oncology Platform

4M ago

Noxopharm Plans CEO Option Grant Tied to Long-Term Share Price Growth

Company Announcements

Noxopharm Plans CEO Option Grant Tied to Long-Term Share Price Growth

4M ago

Noxopharm Taps Novotech to Advance SOF-SKN Toward Key FDA Milestone

PremiumCompany Announcements

Noxopharm Taps Novotech to Advance SOF-SKN Toward Key FDA Milestone

5M ago

Noxopharm Data Backs SOF-16’s Anti-Inflammatory Potential in Autoimmune Disease

PremiumCompany Announcements

Noxopharm Data Backs SOF-16’s Anti-Inflammatory Potential in Autoimmune Disease

5M ago

Noxopharm Names CFO Shawn van Boheemen as New Company Secretary

PremiumCompany Announcements

Noxopharm Names CFO Shawn van Boheemen as New Company Secretary

5M ago

Noxopharm deepens Sofra push with Tezcat deal, CEO shift and key trial progress

PremiumCompany Announcements

Noxopharm deepens Sofra push with Tezcat deal, CEO shift and key trial progress

5M ago

Noxopharm’s SOF-SKN shows prolonged skin retention in preclinical study

PremiumCompany AnnouncementsNoxopharm’s SOF-SKN shows prolonged skin retention in preclinical study

5M ago

Noxopharm Tightens Disclosure Controls After CEO Resigns and Director Notices Updated

Company Announcements

Noxopharm Tightens Disclosure Controls After CEO Resigns and Director Notices Updated

5M ago

Noxopharm CEO Resigns as Biotech Awaits Successor Amid Strategic Shift

Company Announcements

Noxopharm CEO Resigns as Biotech Awaits Successor Amid Strategic Shift

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >